Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

View:
Post by zebTrader on Dec 08, 2017 2:12pm

Reason for +10%

I guess this is the reason for the uptrend:

https://www.marketwatch.com/story/valeant-stock-jumps-8-after-positive-patent-litigation-developments-2017-05-11-15914543
Comment by fdfd12 on Dec 08, 2017 2:19pm
Don't be an idiot. That is from May 2017
Comment by zebTrader on Dec 08, 2017 2:36pm
My bad, sorry about that...
Comment by fdfd12 on Dec 08, 2017 2:40pm
Sorry for the insult.
Comment by Safetrader on Dec 09, 2017 8:08am
Maybe a little of this... https://www.bnn.ca/market-call/benj-gallander-discusses-valeant-pharmaceuticals~1280693
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities